Here is mynon-expert take on the 2nd and 3rd paragraphs of today’s announcement.
Satellite ground stations record a wide range of spectral data of (all) points on earth, from the infrared to the ultraviolet and beyond. An expert in this technology can pick a given point on the ground (for example where there is a known spodumene-bearing pegmatite – such as at Cancet) and dial through the recorded spectrum (or spectra) until some colour (real or false colour as they say in satellite-speak) stands out like a bruised thumb compared to its surroundings. Then all other places with similar/identical rock will also show the same bruised thumb appearance (that is, spectral signature).
The conceptis really that simple. If a light is shone at a known cat’s eye and it reflects, all the other (semi-camouflaged) cat eyes can easily be revealed by the same light. So I have every reason to be bullish that a field crew will find pegmatite, and quite probably spodumene-bearing pegmatite, at some or all of the sites of the red splotches.
The realissue, then, is just how much spodumene will be found in the pegmatites atthose locations, and in what concentrations? We may very well know within a month or two.
I must addthat not every red splotch will be a winner, but it will only take one outsideof the 14 claims. And if MetalsTech does find another important lithium deposit on non-contested land, and begin to develop it, it might just (passively!) allow the 14 contested claims to expire (if the agreement with Luke Schuss et al doesn’t cover that scenario) and strike a deal with the next (lucky) staker/owner.
- Forums
- ASX - By Stock
- MTC
- Ann: Cancet Spodumene Remote Sensing Study
MTC
metalstech limited
Add to My Watchlist
3.85%
!
13.5¢

Ann: Cancet Spodumene Remote Sensing Study, page-23
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
13.5¢ |
Change
0.005(3.85%) |
Mkt cap ! $28.17M |
Open | High | Low | Value | Volume |
13.5¢ | 13.5¢ | 13.5¢ | $3.713K | 27.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 67188 | 13.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.5¢ | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 67188 | 0.130 |
4 | 44619 | 0.125 |
3 | 138341 | 0.120 |
1 | 10000 | 0.100 |
1 | 10500 | 0.094 |
Price($) | Vol. | No. |
---|---|---|
0.135 | 1000 | 1 |
0.140 | 18675 | 2 |
0.145 | 126965 | 4 |
0.150 | 50000 | 1 |
0.155 | 35745 | 1 |
Last trade - 14.10pm 27/06/2025 (20 minute delay) ? |
Featured News
MTC (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online